Hoth Therapeutics (NASDAQ:HOTH) Issues Earnings Results

by · The Cerbat Gem

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.17) earnings per share (EPS) for the quarter, FiscalAI reports.

Hoth Therapeutics Stock Down 4.9%

Shares of NASDAQ HOTH traded down $0.03 during mid-day trading on Friday, hitting $0.63. 291,498 shares of the company were exchanged, compared to its average volume of 401,654. The stock has a 50 day simple moving average of $0.78 and a 200-day simple moving average of $0.98. Hoth Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.12. The firm has a market cap of $12.11 million, a price-to-earnings ratio of -0.70 and a beta of 0.57.

Institutional Trading of Hoth Therapeutics

Institutional investors have recently modified their holdings of the business. Lido Advisors LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter valued at approximately $32,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter valued at approximately $51,000. Geode Capital Management LLC boosted its stake in shares of Hoth Therapeutics by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after buying an additional 9,071 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter valued at approximately $184,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter valued at approximately $232,000. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOTH. Weiss Ratings restated a “sell (d-)” rating on shares of Hoth Therapeutics in a research note on Friday, April 24th. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Wednesday, March 25th. Finally, Wall Street Zen downgraded Hoth Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.00.

View Our Latest Stock Analysis on HOTH

Hoth Therapeutics Company Profile

(Get Free Report)

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.

Further Reading